Table 1 Societal costs associated with ADPKD in the US in 2018
From: The societal economic burden of autosomal dominant polycystic kidney disease in the United States
Component1 | Excess costs (2018 USD) |
|---|---|
Excess direct healthcare costs | |
 CKD stage 1 | $545,894,174 |
 CKD stage 2 | $612,261,195 |
 CKD stage 3 | $619,300,610 |
 CKD stage 4 | $354,143,587 |
 CKD stage 5 (excluding ESRD-RRT) | $442,190,064 |
 ESRD-RRT | $3,167,501,412 |
 Total excess direct healthcare costs | $5,741,291,041 |
Excess direct non-healthcare costs | |
 Research, training, and advocacy | $35,714,993 |
 Costs of matching donors and recipients for kidney transplant | $7,583,334 |
 Costs of transportation to and from dialysis center | $81,428,941 |
Total excess direct non-healthcare costs | $124,727,268 |
Excess indirect costs | |
 Unemployment | $783,819,493 |
  CKD stages 1–3 | $256,201,951 |
  CKD stages 4–5 (excluding ESRD-RRT) | $115,955,070 |
  ESRD-RRT | $411,662,472 |
 Reduced productivity at work | $390,316,213 |
  CKD stages 1–3 | $237,533,624 |
  CKD stages 4–5 (excluding ESRD-RRT) | $59,850,579 |
  ESRD-RRT | $92,932,010 |
 Productivity loss from premature mortality | $196,789,459 |
  Caregivers’ productivity loss | $53,060,981 |
   CKD stages 1–3 | $7,086,663 |
   CKD stages 4–5 (excluding ESRD-RRT) | $9,689,005 |
   ESRD-RRT | $36,285,312 |
  Caregivers’ direct healthcare costs | $16,831,670 |
   CKD stages 1–3 | $7,712,428 |
   CKD stages 4–5 (excluding ESRD-RRT) | $1,210,672 |
  ESRD-RRT | $7,908,570 |
 Total excess indirect costs | $1,440,817,816 |
Total excess direct healthcare, direct non-healthcare, and indirect costs | $7,306,836,126 |